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within 1 cycle. At 12 months, the complete response rate
was 58% and at 24 months, organ response rates were 70%.
The major barrier to widespread implementation of
stem cell transplantation is the high treatment-related
mortality. In the current article, Sanchorawala et al.
report therapy-related mortality of 8.5%. The group from
Oregon had therapy-related mortality of 9.6% [7], and the
group at Memorial reported 10% treatment-related mor-
tality [8]. These therapy-related mortality rates are
increasingly difﬁcult to justify as new active agents for the
treatment of immunoglobulin light chain amyloidosis
become available. It will be important to properly select
patients at high risk of therapy-related death for exclusion
to achieve the optimal outcomes when combining new
antiplasma cell agents with myeloablative therapy and
stem cell rescue.ACKNOWLEDGMENTS
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Accepted 15 May 2015It is an old platitude that peripheral blood counts are
important in acute myeloid leukemia (AML). Most imme-
diately, they are directly related to the risk of potentially
life-threatening medical events such as bleeding orinfections and, to prevent these events, costly supportive
care needs that are associated with unwanted side effects
and reduced quality of life. For patients who have under-
gone initial chemotherapy and have achieved signiﬁcant
cytoreduction, as indicated by the presence of < 5% blasts
by morphology in the bone marrow and resolution of
extramedullary leukemia, peripheral blood counts also
provide relevant prognostic information. Speciﬁcally,
among such responders, patients who show complete re-
covery of their neutrophil and platelet counts have
repeatedly demonstrated better overall survival, higher
expectation of long-term survival (“cure”), and lower risk
of disease recurrence than those who fail to fully recover
either neutrophils or platelets [1-3]. These differences
support and validate the current recommendations by in-
ternational working groups to separate patients who have
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obtained a CR with incomplete platelet recovery (CRp) or a
CR with incomplete blood count recovery (CRi) [4,5].
However, blood counts are not independent of other risk
factors. The likelihood of achieving a CRp rather than a CR is
associated with adverse disease characteristics, including
cytogenetic risk and a history of antecedent hematological
disorder or prior exposure to radiation or chemotherapy [2].
Moreover, higher proportions of patients with CRi or CRp
have morphologic remissions with persistence of minimal
residual disease (MRD) [3]. Still, even after adjustment for
pretreatment risk factors and MRD status, blood counts at
the time of response convey prognostic information for
reasons that are currently not understood [3]. Given the
prognostic role of peripheral blood counts following
chemotherapy after initial diagnosis, it is natural to wonder
what peripheral blood counts at the time of allogeneic he-
matopoietic cell transplantation (HCT) tell us about post-
transplantation outcomes in patients with AML.
This question underlies the study by Vu et al. reported in
this issue of Biology of Blood and Marrow Transplantation
[6]. The investigators analyzed a cohort of 270 patients with
AML in morphologic remission who underwent a ﬁrst
matched related or matched unrelated allogeneic HCT after
myeloablative or reduced-intensity conditioning at their
institution between 2006 and 2013. In line with other
studies analyzing AML patients in remission [1-3,7], the vast
majority of subjects in their cohort met criteria for CR (n ¼
206 [76%]); smaller numbers of patients were in CRp (n ¼
45 [17%]) or morphologic leukemia-free state (MLFS, n ¼ 19
[7%]), and there were no CRi patients. International working
groups have attempted to distinguish MLFS (no requirement
for peripheral blood count recovery) from CRi (residual
neutropenia and/or thrombocytopenia) for patients with <
5% marrow blasts and lack of extramedullary leukemia [4,5].
Nonetheless, in clinical practice, the separation is oftentimes
blurry, and some of the patients with MLFS in this study
may have met the criteria for CRi.
The ﬁndings by Vu et al. are reassuring for patients
presenting with CRp at the time of allogeneic HCT. Although
the 3-year event-free survival appeared slightly lower (36%
versus 45%), their overall and event-free survival were not
statistically signiﬁcantly different from those for patients in
CR after adjustment for various risk factors (including age,
donor-patient gender mismatch, disease etiology, and cy-
togenetic risk) using propensity-score matching. This
observation is consistent with data obtained in a cohort of
99 patients undergoing allogeneic HCT for AML in ﬁrst CR at
the Fred Hutchinson Cancer Research Center: in these pa-
tients, we found that the lack of full blood count recovery
was associated with only a trend toward worse outcomes in
univariate analyses (eg, unadjusted hazard of overall mor-
tality, failure for disease-free survival relapse, and non-
relapse mortality of 2.2 [P ¼ .08], 2.0 [P ¼ .10], 1.7 [P ¼ .36],
and 2.8 [P¼ .12]), respectively [8]. One can merely speculate
why there is no signiﬁcant difference in outcome between
CR and CRp patients in this treatment situation. As an
exciting possibility, it is conceivable that allogeneic HCT
could overcome the negative effect associated with
incomplete blood count recovery, as the authors posit.
However, alternative explanations, such as sample size
limitations and imbalances in patient- and treatment-
characteristics for which appropriate adjustments could
not be made, will need to be considered for the lack of in-
dependent association between CR/CRp status andoutcome. The latter possibilities are suggested by a rela-
tively large study by Alatrash et al. [7]. In their cohort of 334
patients with AML (n ¼ 324) and high-risk myelodysplastic
syndrome (n ¼ 10), the unadjusted hazards for overall
mortality, failure of progression-free survival, and non-
relapse mortality were 2.0 (P <.001), 1.7 (P ¼ .001), and 1.7
(P ¼ .03), respectively, for the 78 CRp patientsdhazard es-
timates that are remarkably similar to those found in the
Fred Hutchinson Cancer Research Center cohort [8].
Although results from formal multivariate analyses were
not reported, Alatrash et al. noted that the CR/CRp status
was the only signiﬁcant predictor of survival in univariate
analyses [7].
On the other hand, the data presented by Vu et al. for the
19 MLFS patients are much more troubling: although after
adjustment their overall survival and event-free survival at
3 years was not statistically signiﬁcantly different from pa-
tients in CR, their nonrelapse mortality was much higher
than that for CR or CRp patients (58% versus 22% versus
16%). Given the very small sample size, drawing ﬁrm con-
clusions is obviously difﬁcult, and it is plausible that this
high nonrelapse mortality rate is a chance ﬁnding; some of
the causes of death listed indeed suggest that this might be
the case. However, it is interesting to note that MLFS pa-
tients more likely had persistent cytogenetic and/or mo-
lecular abnormalities in the pretransplantation bone
marrow sample than the CR and CRp patients did. Although
not collected systematically in this cohort, this suggests that
MLFS patients more likely had MRD at the time of trans-
plantation. In our own AML remission patients, we have
repeatedly observed that, at least after myeloablative con-
ditioning, nonrelapse mortality is higher for those pre-
senting with MRD [8,9]. Thus, despite the limitation of small
sample size, the study by Vu et al. suggests the possibility
that the tolerance for allogeneic HCT is signiﬁcantly lower if
the patient presents with lack of peripheral blood count
recovery at the time of transplantation. If substantiated by
future studies, it will be important to understand the basis
for this association, ie, to dissect whether this association is
the direct results of low blood counts are a consequence of
another factor that tracks along with low blood counts, to
devise the best possible strategy to render transplantation
safer for these patients.ACKNOWLEDGMENTS
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